Has Matthew Karen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $6,234 in general payments to Matthew Karen, MD across 144 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Karen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Karen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Karen, MD

Otolaryngology · Stockbridge, GANPI 1477519833

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,891 of the $6,234 with a category attached, or 62.4%. It is spread thinly across 22 manufacturers, the largest accounting for just 22.7%. 2025 is the largest year on record at $1,931, 6.0 times the $322 reported in 2019. Among otolaryngology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,234in general payments, 2019–2025

Across 144 payments — averaging $43.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Inspire Medical Systems, Inc.$1K
Aerin Medical Inc.$1K
Stryker$1K
Galderma Laboratories, L.p.$564
Medtronic$315
AbbVie$291
plus $1K from 16 others

What the payments were for

Consulting fees$3005%
Travel & lodging$2,04333%
Food & beverage$3,89162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Inspire Medical Systems, Inc.	24	$1,418
Aerin Medical Inc.	9	$1,418
Stryker	7	$1,019
Galderma Laboratories, L.p.	40	$564
Medtronic(2 entities)	3	$315
AbbVie(2 entities)	15	$291
GSK	13	$240
Spirair, Inc.	1	$191
Sanofi	8	$165
Regeneron Healthcare Solutions, Inc.	3	$156
Merz North America, Inc.	1	$56
Baxter Healthcare	2	$55
Mylan Specialty L.p.	3	$50
Boehringer Ingelheim	3	$47
Integra Lifesciences Corporation	2	$41
Sunovion Pharmaceuticals Inc.	2	$40
Intersect ENT, Inc.	1	$39
Lumenis, Inc	1	$34
Optinose US, Inc.	2	$31
Philips North America LLC	2	$28
Ambu Inc.	1	$19
Novartis	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VIVAER STYLUS$1,047
SCOPIS ENT$792
Inspire$466
SeptAlign$382
TURBALIGN$382
Inspire Upper Airway Stimulation System$266
AUDION ET DILATION SYSTEM$136
DUPIXENT$121

How this compares

$6,234 in reported general payments places this provider in the 90th percentile of 308 otolaryngology providers in Georgia.

See all otolaryngology providers in Georgia →

Medicare billing

Part B allowed, 2024

$39,125

Medicare patients

197

Services billed

370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort	16	$916
Azelastine Hcl	19	$812
Montelukast Sodium	101	$781
Fluticasone Propionate	44	$693
Ipratropium Bromide	19	$292
CefuroximeCefuroxime Axetil	18	$178
Cephalexin	12	$178
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	11	$56

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Stockbridge

Howard HermanStockbridge$7K
Dozier HoodFayetteville$347K
Christopher MelroySavannah$298K
Karen HoffmannAtlanta$223K
Jose StolovitzkyAtlanta$81K
Jonathan LindmanEvans$55K
Gregory PostmaAugusta$37K
Oswaldo HenriquezSmyrna$15K
Donald BrowningLawrenceville$14K
Robert GadlageDuluth$14K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →